دورية أكاديمية
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis
| العنوان: | Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis |
|---|---|
| المؤلفون: | Buonerba C., Iaccarino S., Dolce P., Pagliuca M., Izzo M., Scafuri L., Costabile F., Riccio V., Ribera D., MUCCI, BRIGITTA, Carrano S., Picozzi F., Bosso D., Formisano L., Bianco R., De Placido S., Di Lorenzo G. |
| المساهمون: | Buonerba, C., Iaccarino, S., Dolce, P., Pagliuca, M., Izzo, M., Scafuri, L., Costabile, F., Riccio, V., Ribera, D., Mucci, Brigitta, Carrano, S., Picozzi, F., Bosso, D., Formisano, L., Bianco, R., De Placido, S., Di Lorenzo, G. |
| سنة النشر: | 2019 |
| المجموعة: | IRIS Università degli Studi di Napoli Federico II |
| مصطلحات موضوعية: | Epidermal growth factor receptor tyrosine kinase inhibitor, Non-small cell lung cancer, Sex |
| الوصف: | Some commonly available patient or disease characteristics may be associated with progression-free survival (PFS) and overall survival (OS) in EGFR-mutant non-small cell lung cancer (NSCLC) patients receiving EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors). We performed a systematic review and meta-analysis of randomized control trials (RCTs) to explore differences in outcomes associated with EGFR-TKIs among subgroups of EGFR-mutant NSCLC patients. Pooled HRs for progression or death (PFS-HRs) and pooled HRs for death (OS-HRs) were compared among sub-groups defined according to baseline clinical and demographic variables as well as type of EGFR mutation. In the entire assessable population of 4465 EGFR-mutant NSCLC patients, significant interactions with PFS were found for gender (males vs. females; pooled ratio of the PFS-HRs = 1.2; 95% CI 1.12-1.56), smoking history (smokers vs. non-smokers; pooled ratio of the PFS-HRs = 1.26; 95% CI 1.05-1.51), and type of EGFR mutation (patients with exon 21 L858R mutation vs. exon 19 deletion; pooled ratio of the PFS-HRs = 1.39; 95% CI 1.18-1.63). Male patients, smokers and patients with EGFR exon 21 L858R mutation may derive less benefit from EGFR-TKIs compared to female patients, non-smokers and patients with EGFR exon 19 deletion. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/wos/WOS:000489719000044; volume:11; issue:9; firstpage:1259; journal:CANCERS; http://hdl.handle.net/11588/765630Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85071986072; https://www.mdpi.com/2072-6694/11/9/1259/pdfTest |
| DOI: | 10.3390/cancers11091259 |
| الإتاحة: | https://doi.org/10.3390/cancers11091259Test http://hdl.handle.net/11588/765630Test https://www.mdpi.com/2072-6694/11/9/1259/pdfTest |
| رقم الانضمام: | edsbas.82B374CB |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers11091259 |
|---|